Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Net Income: 2012-2025

Historic Net Income for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -$18.6 million.

  • Enanta Pharmaceuticals' Net Income rose 35.08% to -$18.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$81.8 million, marking a year-over-year increase of 29.41%. This contributed to the annual value of -$81.8 million for FY2025, which is 29.41% up from last year.
  • Enanta Pharmaceuticals' Net Income amounted to -$18.6 million in Q3 2025, which was down 1.82% from -$18.3 million recorded in Q2 2025.
  • Enanta Pharmaceuticals' Net Income's 5-year high stood at -$18.3 million during Q2 2025, with a 5-year trough of -$39.1 million in Q2 2023.
  • For the 3-year period, Enanta Pharmaceuticals' Net Income averaged around -$27.5 million, with its median value being -$28.1 million (2023).
  • In the last 5 years, Enanta Pharmaceuticals' Net Income tumbled by 503.91% in 2021 and then soared by 42.00% in 2024.
  • Enanta Pharmaceuticals' Net Income (Quarterly) stood at -$30.1 million in 2021, then increased by 3.75% to -$29.0 million in 2022, then fell by 15.25% to -$33.4 million in 2023, then surged by 33.28% to -$22.3 million in 2024, then soared by 35.08% to -$18.6 million in 2025.
  • Its last three reported values are -$18.6 million in Q3 2025, -$18.3 million for Q2 2025, and -$22.6 million during Q1 2025.